Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04495712 · ClinicalTrials.gov registry record · Phase 4

Antiarrhythmic Effects of Spironolactone in Patients With ICDs

A Phase 4 study of Ventricular Arrhythmias, sponsored by VA Office of Research and Development.

Completed
Registry status
Phase 4
Development phase
90
Enrollment target
1
Study location

NCT04495712 is a Phase 4 study of Ventricular Arrhythmias that has completed, run by VA Office of Research and Development. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04495712, a Phase 4 study of Ventricular Arrhythmias, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
Phase 4
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

This study will test whether spironolactone, an approved drug for among other things hypertension, will reduce the risk of severe arrhythmias in patients with implanted defibrillators. Half the patients in the study will get spironolactone and half will get a placebo. Neither the patients or their providers will know if they are getting spironolactone or placebo.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG spironolactone

Study Locations (1)

Oregon

  • VA Portland Health Care System, Portland, OR - Portland

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2004-07-28
Est. Completion 2008-05-28
Phase Phase 4

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT04495712

The ClinicalTrials.gov registry entry for NCT04495712 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ventricular Arrhythmias appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT04495712 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT04495712 about?

NCT04495712 is a clinical study titled "Antiarrhythmic Effects of Spironolactone in Patients With ICDs". This study will test whether spironolactone, an approved drug for among other things hypertension, will reduce the risk of severe arrhythmias in patients with implanted defibrillators. Half the patients in the study will get spironolactone and half will get a placebo. Neither the patients or their p...

What is the current status of trial NCT04495712?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2004-07-28. Estimated completion is 2008-05-28.

What conditions does trial NCT04495712 study?

This clinical trial studies the following conditions: Ventricular Arrhythmias.

What interventions are being tested in trial NCT04495712?

The interventions under investigation include: placebo (DRUG), spironolactone (DRUG).

Who is sponsoring clinical trial NCT04495712?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04495712 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ventricular Arrhythmias

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.